ERR2278884
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- MYC_TARGETS_V2+0.330
- E2F_TARGETS+0.320
- G2M_CHECKPOINT+0.300
- ANGIOGENESIS+0.260
- HEDGEHOG_SIGNALING+0.230
- MITOTIC_SPINDLE+0.140
- COAGULATION+0.130
- MYC_TARGETS_V1+0.130
- UV_RESPONSE_DN+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.410
- INTERFERON_GAMMA_RESPONSE-0.400
- OXIDATIVE_PHOSPHORYLATION-0.370
- IL6_JAK_STAT3_SIGNALING-0.350
- ALLOGRAFT_REJECTION-0.310
- BILE_ACID_METABOLISM-0.280
- INFLAMMATORY_RESPONSE-0.250
- TNFA_SIGNALING_VIA_NFKB-0.250
- P53_PATHWAY-0.240
- ADIPOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2bd9ef82-12dc-4dcb-8a2c-c58cdf463116 | — | — | 0.825 |
| 2 | b0be4742-ccb7-48e2-b756-0c384321114e | — | — | 0.804 |
| 3 | TCGA-21-1081-01A-01R-0692-07 | — | cohortSQ1 | 0.800 |
| 4 | C3L-02358 | — | cohortSQ1 | 0.791 |
| 5 | SRR8518399 | — | E | 0.790 |
| 6 | TCGA-AN-A0FY-01A-11R-A034-07 | — | B | 0.781 |
| 7 | BS_29X4ZX6Q | high-grade glioma | — | 0.774 |
| 8 | TCGA-BA-A8YP-01A-11R-A39I-07 | — | — | 0.772 |
| 9 | 53bd217b-0458-4315-a13c-f9e79fa46501 | — | — | 0.766 |
| 10 | SJEPD001544_D1.RNA-Seq | EPN | Supratentorial EPN | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |